Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Perche, Federico; Torchilin, Vladimir P.

doi:10.1155/2013/705265

Cited by 195 publications

(148 citation statements)

References 372 publications

Supporting

Mentioning

144

Contrasting

Order By: Relevance

“…Liposome-based nanoparticles have been used previously as drug carry systems because they can be readily modified and generally exhibit good compatibility towards a range of different therapeutic agents, including small molecules, proteins and even short interfering RNA [3][4][5] . Although a variety of different strategies have been proposed to improve the properties of drug-loaded liposomes, including efforts to prolong their circulation time, increase their internalization, and improve their target efficacy, research in these areas has so far been largely unsuccessful and the development of a multitask delivery platform is therefore still urgently required 6 .…”

mentioning

confidence: 99%

Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment

et al. 2014

View full text Add to dashboard Cite

Specific targeting and cellular internalization are key properties for carriers of antitumor therapeutic agents. Here, we develop a drug carrier through the attachment of substrate of endoprotease legumain, alanine-alanine-asparagine (AAN), to cell-penetrating peptides (TAT, trans-activating factor). The addition of the AAN moiety to the fourth lysine in the TAT creates a branched peptide moiety, which leads to a decrease in the transmembrane transport capacity of TAT by 72.65%. Legumain efficiently catalyses the release of TAT-liposome from the AAN-TAT-liposome and thereby recovers the penetrating capacity of TAT. Doxorubicin carried by the AAN-TAT-liposome led to an increase in the tumoricidal effect of doxorubicin and a reduction in its systemic adverse effects in comparison with doxorubicin carried by a control delivery system. Thus, the specific targeting and high efficiency of this delivery platform offers a novel approach to limit the toxicity of anticancer agents as well as increasing their efficacy in cancer therapy.

show abstract

mentioning

confidence: 99%

Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[36,37] Liposomes are lipid-based vesicles that can carry hydrophilic molecules in their aqueous compartment or they can carry hydrophobic molecules in their lipid bilayer. [38] Dendrimers have repeating branches stemming from a central core. The branches can present both drug and a targeting agent.…”

Section: Current Methods In Nanotechnology For Targeting and Deliverymentioning

confidence: 99%

Emerging therapies for pancreatic ductal carcinoma

Falcone

Davis

Stain

et al. 2016

JST

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor mass that grows and metastasizes rapidly. There are no definitive methods for early detection and most patients are diagnosed at a late stage. Those diagnosed at an early stage are eligible for tumor resection. However, many of these patients are soon burdened with tumor recurrence. The tumor grows back aggressively and with resistance to the original chemotherapy. Gemcitabine has been the treatment of choice, but provides only minimal survival prolongation. Researchers are trying to improve the current standard of care by finding different methods to improve treatment efficacy and reduce side effects. This review emphasizes recent data on targeting the tumor using antifibrotic, nanotargeted, and dendritic cell therapies. Antifibrotic therapy aims to reduce tumor fibrosis, which prevents adequate chemotherapy penetration. Nanotargeted therapy offers precise targeting of cancer cells and chemotherapy delivery. Dendritic cell vaccines stimulate the body's immune system to target PDAC cells. These three treatment methods or a combination of them might improve the lifespan and quality of life for PDAC patients.

show abstract

“…The concept of increasing drug targeting through triggered release is based on utilizing subtle pathological changes in the tumor microenvironment and has been extensively studied in the past years for improved efficiency of liposomal drug release [12,51]. The stimuli-sensitive nanocarriers maintain their stealth function throughout circulation, and upon arrival at the specific tumor site, undergo rapid changes, such as aggregation, disruption, and permeability changes, which trigger drug release when exposed to a particular tumor microenvironment [2,52,53].…”

Section: Stimuli-sensitive Liposomesmentioning

confidence: 99%

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Porfire¹,

Achim²,

Tefas³

et al. 2017

Liposomes

View full text Add to dashboard Cite

The liposomes present great potential for applications in targeted delivery of chemotherapeutics in the treatment of cancer. The use of liposomal drug carriers as vehicles for targeting of chemotherapeutic agents to tumor tissues is based on their advantages over other dosage forms, represented by their low systemic toxicity, their bioavailability, and their possibility to enhance the solubility of different chemotherapeutic agents, due to the ability to encapsulate both hydrophilic and lipophilic drugs. They enhance the therapeutic index of anticancer drugs by increasing the drug concentration in tumor cells through tumor targeting. The available approaches used for tumor targeting using liposomes are passive targeting, active targeting, and triggered drug release. The most advanced targeting strategies proposed for cancer treatment are the development of multifunctional liposomes, having combined targeting mechanism. In this chapter, the tumor-targeting mechanisms are described in detail as well as the possibilities to design the targeted liposomal nanocarrier in order to reach the desired target in the body and minimizing the off-target effects. Moreover, the current status of preclinical and clinical evaluation is highlighted.

show abstract

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Cited by 195 publications

References 372 publications

Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment

Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment

Emerging therapies for pancreatic ductal carcinoma

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Contact Info

Product

Resources

About